Literature DB >> 7530624

Trough/peak ratios for antihypertensive agents. The issues in perspective.

P A Meredith.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 7530624     DOI： 10.2165/00003495-199448050-00001

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  16 in total

1.  Timing of blood pressure measurements in determining anomalies in duration of effect of an antihypertensive drug: assessment of isradipine.

Authors:  G S Stokes; G M Shenfield; H J Johnston; J F Marwood; F Dunagan; J Boutagy
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

Review 2.  Some problems with antihypertensive drug studies in the context of the new guidelines.

Authors:  M Rose; F G McMahon
Journal:  Am J Hypertens       Date:  1990-02       Impact factor: 2.689

3.  Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension.

Authors:  G Parati; G Pomidossi; F Albini; D Malaspina; G Mancia
Journal:  J Hypertens       Date:  1987-02       Impact factor: 4.844

4.  Antihypertensive effects of nifedipine gastrointestinal therapeutic system on clinic and ambulatory blood pressure in essential hypertensives. Italian GITS Study Group.

Authors:  A Zanchetti; L Bianchi; S Amigoni; S Omboni; A Villani; A Ravogli
Journal:  J Hypertens Suppl       Date:  1993-12

Review 5.  Analysis of ambulatory blood pressure data in antihypertensive drug trials.

Authors:  W B White
Journal:  J Hypertens Suppl       Date:  1991-01

6.  Prognostic value of 24-hour blood pressure variability.

Authors:  A Frattola; G Parati; C Cuspidi; F Albini; G Mancia
Journal:  J Hypertens       Date:  1993-10       Impact factor: 4.844

7.  Evaluation of hypertension and related target organ damage by average day-time blood pressure.

Authors:  A C Pessina; P Palatini; G Sperti; L Cordone; M Libardoni; L Mos; P Mormino; A Di Marco; C Dal Palù
Journal:  Clin Exp Hypertens A       Date:  1985

8.  Pharmacodynamic modeling of the antihypertensive response to amlodipine.

Authors:  R Donnelly; P A Meredith; S H Miller; C A Howie; H L Elliott
Journal:  Clin Pharmacol Ther       Date:  1993-09       Impact factor: 6.875

9.  Patient compliance and therapeutic coverage: amlodipine versus nifedipine (slow-release) in the treatment of angina pectoris. Belgian Collaborative Group.

Authors:  J M Detry; P Block; G De Backer; J P Degaute; R Six
Journal:  J Int Med Res       Date:  1994 Sep-Oct       Impact factor: 1.671

Review 10.  Partial compliance: implications for clinical practice.

Authors:  P Rudd
Journal:  J Cardiovasc Pharmacol       Date:  1993       Impact factor: 3.105
View more
  4 in total

Review 1.  Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension.

Authors:  M Haria; G L Plosker; A Markham
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

Review 2.  Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension.

Authors:  J C Gillis; A Markham
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 3.  Nisoldipine coat-core. A review of its pharmacology and therapeutic efficacy in hypertension.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 4.  Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure.

Authors:  J E Frampton; D H Peters
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.